Detailed long-term dynamics of neutrophil-to-lymphocyte ratio under biologic treatment reveal differential effects of tumour necrosis factor-alpha and interleukin 12/23 antagonists
Psoriasis is thought to be associated with a reduced life expectancy through systemic inflammation. A comparative, retrospective analysis of neutrophil-to-lympho-cyte ratio, a biomarker of systemic inflammation and cardiovascular risk, under 196 treatments with tumour necrosis factor-α and interleuk...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
Sep 30, 2021
|
| In: |
Acta dermato-venereologica
Year: 2021, Volume: 101, Issue: 10, Pages: 1-5 |
| ISSN: | 1651-2057 |
| DOI: | 10.2340/actadv.v101.271 |
| Online Access: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.2340/actadv.v101.271 Verlag, lizenzpflichtig, Volltext: https://medicaljournalssweden.se/actadv/article/view/271 
|
| Author Notes: | Jochen H.O. Hoffmann, Christian Knoop, Alexander H. Enk and Eva N. Hadaschik |
| Summary: | Psoriasis is thought to be associated with a reduced life expectancy through systemic inflammation. A comparative, retrospective analysis of neutrophil-to-lympho-cyte ratio, a biomarker of systemic inflammation and cardiovascular risk, under 196 treatments with tumour necrosis factor-α and interleukin-12/23 antagonists was performed. Neutrophil-to-lympho-cyte ratio decreased significantly within 3 months of initiation of treatment and remained stable at reduced levels for at least 33 months. Dynamics were more pronounced and neutrophil-to-lympho-cyte ratio under treatment was lower in patients treated with tumour necrosis factor-α compared with interleukin-12/23 antagonists (geometric mean (95% confidence interval): 2.03 (1.9, 2.1) vs 2.63 (2.2, 3.2), respectively, p = 0.014). tumour necrosis factor-α antagonist treatment and baseline neutrophil-to-lympho-cyte ratio were independent predictors of a median low cardiovascular risk neutrophil-to-lympho-cyte ratio (< 2.15) during treatment (odds ratio (95% confidence interval): 0.53 (0.4-0.8) and 4.68 (1.0-19.1), p = 0.001 and p = 0.032, respectively). These results demonstrate a rapid and sustained reduction in biomarkers of systemic inflammation under biologic treatment. Furthermore, these data suggest class-specific effects on systemic inflammation, which may be relevant for the prevention of psoriasis co-morbidity by systemic treatment. |
|---|---|
| Item Description: | Gesehen am 06.04.2022 |
| Physical Description: | Online Resource |
| ISSN: | 1651-2057 |
| DOI: | 10.2340/actadv.v101.271 |